glumetinib + docetaxel

A combination therapy of glumetinib (also known as gumarontinib or SCC244), a potent, highly selective, orally bioavailable small molecule inhibitor of the MET proto-oncogene, receptor tyrosine kinase (also known as c-MET or hepatocyte growth factor receptor), and docetaxel, a widely used chemotherapeutic agent that stabilizes microtubules and prevents cell division. This combination is being investigated primarily in MET-overexpressed or MET-altered non-small cell lung cancer (NSCLC) and advanced gastric or gastroesophageal junction adenocarcinoma. Glumetinib inhibits MET-driven signaling pathways, potentially reducing tumor cell proliferation, invasion, survival, and angiogenesis, while docetaxel acts as a cytotoxic agent causing mitotic arrest and cell death. The combination aims to enhance antitumor efficacy by concurrently targeting both oncogenic signaling pathways and cytoskeletal integrity.[1][2][3][4][6][7][8][10]